Recombinant SARS-CoV-2 Spike antibody (AA 319-541)

Catalog No. ABIN7581775

Product Details anti-SARS-CoV-2 Spike Antibody

Target: SARS-CoV-2 Spike

Antibody Type: Recombinant Antibody

Binding Specificity: AA 319-541

Reactivity: SARS Coronavirus-2 (SARS-CoV-2)

Host: Mouse

Expression System: Phage display

Clonality: Monoclonal

Conjugate: This SARS-CoV-2 Spike antibody is un-conjugated

Application: ELISA, Western Blotting (WB), Flow Cytometry (FACS), Immunofluorescence (IF)

Purpose: recombinant anti-SARS-CoV-2 spike antibody

Specificity: This is an antibody developed by antibody phage display technology using a human naive antibody gene library and SARS-CoV-2 antigen. For this antibody both the heavy and light chains are cloned and expressed, generating full-length antibodies.

Cross-Reactivity (Details): No known cross reactivity. No cross-reactivity to other human coronaviruses.

Characteristics: This antibody can be detected with anti-mouse Fc secondary antibodies.

Purification: Protein A purification

Grade: Animal-Free

Immunogen: No immunization, animal-free antibody development. Antigen: Spike Protein SARS-CoV2 RVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNF

Clone: AB68-A09

Isotype: IgG2a

Application Details

Application Notes: Western Blot: 0.2-5 μg/mL ELISA: 1-12 μg/mL as coating antibody 0.5-5 μg/mL as detection antibody IF: 0.1 - 10 μg/mL Optimal working dilution should be determined by the investigator

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 1 mg/mL

Buffer: PBS, pH 7.4,

Storage: -20 °C

Target Details for SARS-CoV-2 Spike

Target: SARS-CoV-2 Spike

Alternative Name: SARS-CoV-2 spike protein (RBD) (SARS-CoV-2 Spike Products)

Background: Coronaviruses (CoVs) are enveloped non-segmented positive-sense single-stranded RNA viruses and can infect respiratory, gastrointestinal, hepatic and central nervous system of human and many other wild animals. Recently, a new severe acute respiratory syndrome β-coronavirus called SARS-CoV-2 (or 2019-nCoV) has emerged, which causes an epidemic of acute respiratory syndrome (called coronavirus human disease 2019 or COVID-19). SARS-CoV-2 shares 79.5 % sequence identity with SARS-CoV and is 96.2 % identical at the genome level to the bat coronavirus BatCoV RaTG133, suggesting it had originated in bats. SARS-CoV-2 contains 4 structural proteins, including Envelope (E), Membrane (M), Nucleocapsid (N) and Spike (S), which is a transmembrane protein, composed of two subunits S1 and S2. The S protein plays a key role in viral infection and pathogenesis. The S1 subunit contains the N-terminal domain (NTD) and a receptor binding domain (RBD), which binds to the cell surface receptor Angiotensin-Converting Enzyme 2 (ACE2) present at the surface of epithelial cells, causing mainly infection of human respiratory cells, whereas S2 harbors heptad repeat 1 (HR1) and HR2. The RBD domain first binds its receptor to form an RBD/ACE2 complex. This triggers conformational changes in the S protein, leading to membrane fusion mediated via HR1 and HR2 and consequently in viral entry into target cells. Antibodies targeting various regions of S protein have different mechanisms in inhibiting SARS-CoV-2 infection. For example, NTD-targeting antibodies bind the NTD to form an NTD/mAb complex, thereby preventing conformational changes in the S protein and blocking membrane fusion and viral entry. RBD-targeting antibodies form RBD/mAb or RBD/Nb complexes that could inhibit binding of the RBD to ACE2, thereby preventing entry of SARS-CoV-2 into target cells.

Molecular Weight: 76 kDa

NCBI Accession: YP_009724390

UniProt: P0DTC2